Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
Date:3/10/2010

On January 21, 2010, BioSpecifics' partner Auxilium announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application for XIAFLEX for the treatment of Dupuytren's contracture commenced. As a result, BioSpecifics will receive a $1.3 million milestone payment from Auxilium.

On December 16, 2009, the Company reported results from a Phase 2b clinical trial of XIAFLEX for the treatment of Peyronie's disease conducted by Auxilium. Overall, XIAFLEX demonstrated a statistically significant change compared to placebo at 36 weeks in both improvement in penile curvature (p=0.001) and the PRO Peyronie's disease bother domain (p=0.046). There was no statistically significant change in mean scores for the PRO penile pain, intercourse discomfort or intercourse constraint domains between XIAFLEX and placebo. XIAFLEX was well-tolerated and the most common treatment related adverse events in the Phase 2b study were consistent with adverse events reported in previous Peyronie's disease trials with XIAFLEX, which included injection site bruising, edema and pain.

On September 3, 2009, The New England Journal of Medicine published data from the pivotal CORD I Phase III clinical trial of XIAFLEX for Dupuytren's contracture.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
2. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
4. BioSpecifics Technologies Corp. Announces FDA Approval of XIAFLEX(TM) for Treatment of Dupuytrens Contracture
5. BioSpecifics Technologies Corp. to Present at the Piper Jaffray 21st Annual Health Care Conference
6. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
7. BioSpecifics Technologies Corp. to Present at Cowen and Company 30th Annual Health Care Conference
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2009 Financial Results on March 10, 2010
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , BURLINGTON, Mass., Oct. 16 Palomar Medical ... researcher and developer of light-based systems for cosmetic ... with Johnson & Johnson Consumer Companies Inc ("JJCC"), ... test and commercialize home-use, light-based devices for (i) ...
... 16 Reportlinker.com announces that a new market ... Reportlinker Adds Pharma 101: An Overview ... , http://www.reportlinker.com/p0155107/Reportlinker-Adds-Pharma-101-An-Overview-of-the-Life-Sciences-Industry-(Analyst-Insight).html , Introduction , ... Without having the proper background, it can be ...
Cached Medicine Technology:Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 2Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 3Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 4Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson 5Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight) 2
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... 2014) ― A new study in the American ... health-related Google searches reveals a recurring pattern that could ... , Investigators from San Diego State University, the Santa ... analyzed "healthy" Google searches (searches that included the term ... in the U.S. from 2005 to 2012. They found ...
(Date:4/17/2014)... of chronic inflammation in non-cancerous prostate tissue may have ... than those with no inflammation, according to results of ... Hopkins Kimmel Cancer Center. , The link between persistent ... so-called high-grade prostate cancer those with a Gleason ... of the most aggressive and rapidly growing prostate cancers. ...
(Date:4/17/2014)... According to a study published today in PLOS ... world where malaria is common can mount an immune ... them to avoid repeated bouts of high fever and ... in their bloodstream. The findings may help researchers develop ... by the malaria parasite. , Each year, approximately 200 ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... several commonly-prescribed dementia drugs may be putting elderly Canadians ... , Cholinesterase inhibitors (Aricept, Exelon and Reminyl) are often ... because they increase the level of a chemical in ... drugs are known to provoke slower heart rates and ...
... Public Welfare Estelle B. Richman today responded to critics ... save taxpayers $146 million annually while preserving consumer benefits ... from the Smart Pharmacy initiative are real, not speculative," ... is facing a budget shortfall now and the savings ...
... pain condition common in people with migraines also ... headache, according to a study conducted by researchers ... for Neuroscience. , Approximately half of a group ... a condition that causes patients to have pain ...
... 27 UNICEF has appealed for an additional ... fighting in northwest Pakistan. Over half of the displaced are ... of supplies and funding. , , Humanitarian ... the number of people fleeing fighting that has taken place ...
... of Tennessee and Daiichi Sankyo ATLANTA, ... headquartered in Atlanta, has recently been awarded business ... BlueShield of Tennessee and Daiichi Sankyo, Inc.Studiocom,s healthcare ... these new clients meeting the challenges of the ...
... DIEGO, May 27 ResMed Inc. (NYSE: RMD ... upcoming conferences. David Pendarvis, SVP Organization Development and General Counsel ... the Four Seasons in Chicago on June 10, 2009 at ... CEO will present at the Jefferies Third Annual Healthcare Conference ...
Cached Medicine News:Health News:Dementia drugs may put some patients at risk, Queen's study shows 2Health News:Secretary of Public Welfare Corrects the Record on 'Smart Pharmacy' Initiative 2Health News:UNICEF Appeals for Funding to Urgently Assist Displaced Children and Women in Northwest Pakistan 2Health News:Studiocom Continues Growth with Healthcare Industry Wins 2Health News:Studiocom Continues Growth with Healthcare Industry Wins 3
... with 24-well x 0.2ml sub-ambient block and ... thermistor) Heating rates: up to 3C/second; Accurate ... Excellent uniformity: better than 0.5C within 15 ... programming: directory program storage of up to ...
... maximizes what a thermal cycler can do ... formats, an easy graphic interface, and best ... PCR. The iCycler thermal cycler will raise ... can do for you.,, iCycler Thermal Cycler ...
Contains: Card, cabling and instructions to remotely access a RoboCycler® instrument from a PC or Macintosh® computer...
... RoboCycler Gradient 40 or 96 temperature cyclers, the ... linear temperature range of up to 14 or ... with a temperature difference of up to 2C ... you can test up to 12 different annealing ...
Medicine Products: